Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel specific polypeptide and application thereof in preparing medicament for diagnosing, preventing and treating severe acute respiratory syndrome caused by coronaviruses

A specific and new technology, applied in the field of new specific peptides, can solve the problems of time-wasting onset, poor specificity, non-toxicity of immunostimulation, etc.

Active Publication Date: 2009-11-11
大连泓亿生物技术有限公司
View PDF0 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For nucleotide vaccines, its immune stimulation is not strong enough and its specificity is not very good
While weak live or inactivated virus vaccines can stimulate the body to produce antibodies, many viruses carry toxic proteins, which can pose safety problems
Vaccines based on viral proteins are relatively effective and safe, but it is difficult to identify a viral protein among various viral proteins, because viral proteins have strong immunostimulatory and non-toxic effects on the body
On the other hand, almost all methods of screening vaccines are based on previous trials and randomized trials, which not only waste a lot of time but also rarely work

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel specific polypeptide and application thereof in preparing medicament for diagnosing, preventing and treating severe acute respiratory syndrome caused by coronaviruses
  • Novel specific polypeptide and application thereof in preparing medicament for diagnosing, preventing and treating severe acute respiratory syndrome caused by coronaviruses
  • Novel specific polypeptide and application thereof in preparing medicament for diagnosing, preventing and treating severe acute respiratory syndrome caused by coronaviruses

Examples

Experimental program
Comparison scheme
Effect test

example 1

[1196] Example 1: SARS polypeptide array chip construction and biological probe detection

[1197] 1.1 Construction of SARS peptide array chip

[1198] The 15 ORFs protein sequences encoded by the entire SARS genome were designed by software system (DIGEN, JeriniBiotools GmbH, Beilin, Germany) and automated equipment (AutoSpot, Intavis Bioanalytical Instruments, Lagenfeld, Germany), and were directly expressed on the cellulose membrane according to the principle of sequence drift. Synthesize the amino acid sequence of the polypeptide, and arrange these overlapping protein polypeptide fragments on the chip at a density of 24 × 18, that is, the Overlapping Peptide Array (Overlapping Peptide Array) technology. PEG-modified cellulose membranes with primary amino groups were also purchased from Intavis, Germany. After each amino acid spotting, react with 0.5 M amino-protecting agent (fmoc) chemically activated by HOBT and DIPC for at least 15 minutes. After removing the protectiv...

example 2

[1202] Example 2: Peptide array chip (membrane) quality detection

[1203] Multiple backup M protein sequence arrays were synthesized on a set of membranes. These replica membranes are used for quality control monitoring and to evaluate the reproducibility and reliability of the results. The peptide array detection results of SARS patients in the acute phase and recovery phase and the control group were used to verify the quality of the peptide array chip. Nine polypeptide sequence sites were randomly selected, and their fluorescence intensity was measured. The results showed that the characteristics and fluorescence intensities of the three replicated M protein sequence arrays (membranes) were very similar, and the average standard deviation (SD) of the relative fluorescence intensities of multiple backup M protein sequence arrays was also very close. In this study, all peptide array chips (membranes) were verified by the same method, and all showed consistent results.

example 3

[1204] Example 3: Analysis of SARS patient serum and normal human serum using peptide array chips

[1205] 3.1 Collection of patient serum and normal human serum

[1206] Sera from 10 SARS-infected patients and 10 normal controls were used for the detection of SARS peptide array chip bioprobes. Serum was collected separately (see Table 3 for serum collection information). Diagnosis is based on patient contact history and confirmed by PCR analysis and antibody testing recommended by the World Health Organization. Serum collection time points in the acute phase were 5 to 13 days (average 6.8 days) after clinical onset. The serum collection time point in the recovery period was 17 to 31 days (average 24.7 days) after clinical onset. Patient 5 died approximately 1 month after clinical onset.

[1207] Table 3 Serum collection information of SARS patients in the acute phase and recovery phase

[1208] case number

Acute phase (days after clinical onset)

Recovery p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses novel specific polypeptide, which comprises 114 novel specific polypeptides, and is characterized in that the novel specific polypeptide has a length of about 8 to 20 amino acids, can establish a model of an SARS virus polypeptide sequence, can react with an antibody in human serum produced by the irritation of SARS viruses and the like. The novel specific polypeptide can be used for preparing a medicament for diagnosing, treating and preventing severe acute respiratory syndrome caused by coronaviruses.

Description

technical field [0001] The invention relates to a biological polypeptide, in particular to a novel specific polypeptide, and the application of the polypeptide in the preparation of medicines for diagnosing, treating and preventing severe acute respiratory syndrome (SARS) caused by coronavirus. Background technique [0002] Severe Acute Respiratory Syndrome (SARS) caused by coronavirus is a serious infectious disease that is very destructive to the lives of patients and socioeconomically. The U.S. Centers for Disease Control provides information on the diagnosis of the SARS virus ( http: / / www.cdc.gov / ncidod / sars / diagnosis.htm ) and coronavirus antibody test ( http: / / www.cdc.gov / ncidod / sars / lab / eia / index.htm )Information. Polypeptide is a chain molecular composition composed of various amino acids connected by covalent bonds. A set of amino acid sequences can be designed using computer software, and a series of polypeptides can be synthesized by a peptide synthesizer. Th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06C07K7/08A61K38/08A61K38/10A61K39/215A61P31/14A61P11/00G01N33/53C12R1/93
Inventor 威廉·坎贝尔贾伟国黄冬
Owner 大连泓亿生物技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com